Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary

August 12, 2021

NASDAQ US Health Care Pharmaceuticals earnings 15 min

Earnings Call Speaker Segments

Jennifer Good

executive
#1

Good afternoon, everyone, and thanks for joining us for the business update and earnings call for the second quarter of 2021. Joining me on today's call, as you just heard, is Dr. Bill Forbes, who serves as our Chief Development Officer — he'll be with me for Q&A once we finish the prepared remarks — and also Lisa Delfini, who has just been named Trevi's Chief Financial Officer. Lisa came on board this week, and I'm delighted to have her as part of the company. On the whole, we've been putting a lot of effort into finishing enrollment for both of our clinical trials. As all of you are aware, conducting clinical trials globally while COVID-19 is circulating has not been easy. Even so, we keep moving forward and expect that data from both trials will be reported in the first half of next year. Every one of these indications stands for a substantial unmet medical need among patients. Let me share some additional detail on each of the trials. The program furthest along in clinical development for us is pruritus and prurigo nodularis, or PN, a serious and debilitating condition marked by papules and nodules appearing on the skin, along with relentless and severe itching. No therapies have been approved for this indication. PN is a chronic disease, and since scratching happens repeatedly, those papules and nodules are able to spread and get worse. We put the global prevalence of PN at roughly 730,000 patients — 300,000 of them in the U.S., with 430,000 across the rest of the world. Even though biologics are also being developed for PN, ours is the sole nonbiologic oral candidate in late-phase development, which we think could give us a meaningful competitive edge and offer patients a valuable option. Right now we're running a Phase IIb/III trial in this condition that we refer to as our PRISM trial. Recruitment for PRISM is happening in the U.S. as well as Europe. More than 60 sites have been activated so far. The study's primary endpoint is a responder analysis built on how much itch intensity drops, measured through the Worst Itch Numerical Rating Scale at 14 weeks, 12 of which consist of blinded fixed dosing. At this point we've randomized about 285 of the 360 subjects planned for the trial — that's roughly 80% of the target enrollment — and we've kept helping our sites locate new subjects for the study through a range of strategies. The feedback we're hearing from sites about the trial encourages us, and we still have more than 95% of eligible subjects completing week 14 and rolling into the open-label extension part of the trial. That gives us long-term safety data, and beyond that, valuable efficacy data concerning skin healing and quality of life for these subjects. Our view is that by addressing the symptomatic endpoint of reducing itch, an effective therapy may be able to break the itch/scratch cycle, which would lead to skin healing and produce disease modifications as time goes on. On our side, we're capturing images at specific locations within the study, and we keep receiving positive stories of success from individuals who have been on treatment for an extended period, and whom we know are taking the drug. When it comes to enrollment, recruitment tends to be sluggish during the summer since everyone goes on holiday, and this year even more so; June saw robust enrollment, while July and August were somewhat slower. We anticipate that September enrollment numbers will return to typical levels once schools reopen and planned time off decreases. Now shifting to our second clinical program, which addresses chronic cough and idiopathic pulmonary fibrosis, or IPF. IPF is a progressive and serious illness characterized by scarring of lung tissue. A major debilitating symptom of this condition is chronic coughing, impacting roughly 70% to 85% of these individuals, and no approved treatments exist for it; within the U.S., we estimate around 130,000 people have IPF, with a comparable number in Europe. Globally, it's estimated that more than 1 million individuals are afflicted by IPF. Given the elevated 5-year mortality rate tied to IPF, those who prescribe and those who suffer from it are seeking not just to decelerate disease progression but also to enhance their quality of life. We're running a Phase II double-blind crossover trial featuring a 14-day washout interval between every 3-week treatment period. The main endpoint evaluation is the average percentage shift in daytime cough frequency relative to baseline. Daytime cough frequency gets tracked using a digital cough monitor across the treatment and placebo groups. This study is presently underway in the U.K. Owing to the lung damage linked to this illness, this trial has been hit harder by COVID-19 constraints compared to our PN study. The shelter-in-place orders for these individuals in the U.K. ended at the close of March, and wider national restrictions were removed in July; we've reopened roughly half of our 15 U.K. sites as we emerge from COVID limitations. And we were happy to observe screening and enrollment activity picking up again at those locations. We've conducted productive advisory board sessions with our sites to gather input on scheduling and ways to assist their enrollment so the trial can be finished. We keep watching the COVID scenario in the U.K. Fortunately, though, IPF patients were given priority for COVID vaccinations. We believe that the majority of these individuals are now completely vaccinated. We'll keep collaborating intently with all our other qualified U.K. sites to get the study entirely up and running with enrollment. As a note, this study aims to enroll about 60 participants, with the objective of achieving 44 who complete it. After joining, a participant needs roughly 70 days to finish the entire study. Given the reopening activity we saw this quarter and what we've heard from our sites, we now have guidance in place for this trial to report top line data during the first half of next year. Beyond our focus on finishing those trials, the team has stayed busy getting ready for the next stage of development for both indications, and we're also assessing other possible indications to develop. On top of that, we're actively publishing our data, taking part in conferences, and doing market research to grasp how our product might be positioned, since that could shape further clinical work. Last quarter we went to the BIO Digital conference in June, where we met with more than 30 companies about potential ex U.S. partnership opportunities. We also recently went to the summer meeting for AAD, where we keep gaining backing from KOLs who have faith in this mechanism for pruritic conditions. So there's a great deal of activity within the company as we get ready for top line data in both trials. Now let me briefly go through our financial results for the second quarter of 2021, and I'm looking forward to handing this financial review to Lisa next quarter. As a reminder, the complete financial results for the second quarter of 2021 are available in our press release issued before this call and in our 10-Q, which was filed with the SEC today after the market closed. For the second quarter of 2021, we reported a net loss of $9.8 million versus a net loss of $7.4 million for the same quarter of 2020. R&D expenses came to $6.5 million during the second quarter of 2021 versus $4.9 million in the same period of 2020. That increase was mainly driven by higher personnel-related expenses, greater enrollment in our ongoing Phase IIb/III PRISM trial, purchases of clinical trial supplies, and higher consulting and professional fees. Those increases were partly offset by lower expenses reflecting the completion of our Phase Ib clinical trial in patients with chronic liver disease in the first half of 2020. G&A expenses were $2.7 million during the second quarter of 2021 versus $2.5 million in the same period of 2020. That increase was mainly due to higher legal and professional fees, partly offset by a reduction in personnel-related expenses. Other expenses also rose by approximately $600,000, representing interest expense on our term loan with SVB, which was executed in August of last year, as well as the commitment to be paid to Lincoln Park Capital for a purchase agreement put in place, under which the company has the right but not the obligation to sell to Lincoln Park up to 15 million of shares of our common stock. Any such sales of common stock will be subject to certain limitations and may occur from time to time over a 24-month period. We have not yet sold any stock under that agreement. At the close of June 30, 2021, the amount we held in cash along with cash equivalents came to $36.4 million, whereas on December 31, 2020, that figure stood at $45 million. Those are all the comments I had ready to deliver. At this point, I'll hand things back to our operator so we can move into the Q&A portion.

Serge Belanger

analyst
#2

My first question concerns the PRISM trial and its enrollment. It appears the slowdown we typically see in summer has indeed shown up. I'm simply wondering what enrollment looks like for you during these summer months. From what I understand, your previous consistent pace was roughly 20 to 30 months — that is, 20 to 30 patients each month. I'd like to know how much that figure has fallen, and whether the recent COVID resurgence has affected you at all up to now.

Jennifer Good

executive
#3

Bill, I'll hand this over to you. You're the one on the ground handling this.

Bill Forbes

executive
#4

Okay, Serge, I appreciate you asking that. The truth is things have moved more slowly, and the stretch of summer was especially tough. We figured plenty of people would be away on holiday. There's a rather curious pattern that has unfolded because of COVID. Naturally, everyone had been shut in and had little desire to venture out, and we've gotten past that stage. Whether the Delta variant is contributing here, I can't say for certain. What I lean toward, when we examine it location by location, is that we simply see many employees and patients alike taking extended time off during those summer months. I suppose everyone missed out on it the previous summer, so this was something we saw coming. We were given advance warning before entering this period; that's the reason we said something on the prior call. Clearly, we're counting on the remainder of August, then September, and the balance of the year to serve as our strongest months for enrollment as we wrap this up. I trust that addresses what you wanted to know.

Serge Belanger

analyst
#5

Right. Then regarding the IPF cost, it appears your sites in the U.K. are returning to operation. In the past, I believe you mentioned possibly adding certain sites in Germany. Has that been ruled out at this point? Do you expect that the quantity of U.K. sites will be sufficient to enroll the number of patients you need?

Bill Forbes

executive
#6

Yes, we do. Germany was removed from consideration since we believed the resources would be put to better use in the U.K., and the manner in which these patients are treated within the trust, within the U.K. health system, truly gave us the strongest chance to enroll this small study; just this week we've had 3 screens. So I mean it has genuinely accelerated a fair amount. Therefore we expect, once more, as we move past this summer month of August, in particular, we expect this to proceed. And as Jennifer mentioned before, I mean, 50% of the sites are operational and looking for patients; we're hoping to get the remaining ones going shortly. So I think right now, we feel the sites we possess are those we can proceed with here. And the expectation is that we can finish enrollment during this year and report out in the first half of next year.

Serge Belanger

analyst
#7

Congrats on the progress.

Jennifer Good

executive
#8

Thank you, serge.

Jennifer Good

executive
#9

We appreciate everyone taking the time to join and take part in today's call. Our thanks also go out to the team at Trevi, the investigators on our study, and every subject who keeps taking part in our clinical trials. Enjoy what's left of the summer, all of you, and we can't wait to tell you about our progress once fall arrives. Thanks so much.

Operator

operator
#10

That wraps up our call. We appreciate everyone joining us for today's presentation. You're free to leave the line at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.